<DOC>
	<DOCNO>NCT00253461</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography ( PET scan ) use 11C topotecan , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This phase I/II trial study well PET scan use 11C topotecan predicts response treatment patient brain metastasis due ovarian , small cell lung , cancer .</brief_summary>
	<brief_title>11C Topotecan PET Imaging</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tumor uptake ^11C topotecan occurs quickly enough sufficient concentration measure immediately follow infusion patient brain metastasis secondary ovarian cancer , small cell lung cancer , cancer . - Determine , preliminarily , ^11C image potential early predictor response topotecan therapy patient . Secondary - Determine whole-body biodistribution ^11C topotecan patient . OUTLINE : - Phase I : Patients receive ^11C topotecan IV 10 minute follow immediately 1-2 hour positron emission tomography ( PET ) scan . Within 4 week initial imaging , patient also undergo CT scan . - Phase II : Patients receive ^11C topotecan undergo image phase I . Patients also receive fludeoxyglucose F 18 IV , 1 hour later , undergo PET scan . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian cancer , small cell lung cancer , cancer Metastatic brain disease Eligible topotecan therapy Measurable disease CT scan and/or MRI PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy More 3 month Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Not specify Renal Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Adequate endorgan function Able tolerate lie radiology table ≥ 1 hour No serious medical psychiatric illness would preclude study compliance give informed consent PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>